Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/428—Thiazoles condensed with carbocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
  • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
  • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/24—Heavy metals; Compounds thereof
  • A61K33/26—Iron; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system

Definitions

• the present invention relates to a method of treating and diagnosing restless legs syndrome including periodic limb movements during sleep and to a means for carrying out the method.
• RLS Restless Leg Syndrome
• Activities that require maintaining motor rest and include limited cognitive stimulation such as transportation (travelling by car, plane, train, etc.) or attending longer meetings, lectures, movies or other performances, become difficult or even impossible.
• the symptoms typically worsen during the evening and early night period a subgroup of RLS patients actually experience great difficulties to sleep and insomnia is frequently a prominent complication.
• the symptoms have a considerable negative impact on quality of life. They can typically be relieved by movement, such as standing up, moving around, or short walks. However, the symptoms may return with increased intensity shortly after such activities. If an RLS patient is forced to lay still, symptoms will continue and may led to involuntary movements.
• PLMS periodic limb movements during wakefulness
• PLMW periodic limb movements during wakefulness
• PLMS are best described as rhythmic extensions of the foot, big toe and dorsal flexions of the ankle. Occasionally, this movement is accompanied by flexion of the knee and hip. The movements last for approximately 0.5 to 5 seconds and appear with a frequency of about one every 20 to 40 seconds. PLMS occur in cluster episodes, each of which lasts several minutes or even hours. PLMS/PLMW and RLS may be found independently from each other but epidemiological data suggests that approximately 90% of RLS patients also have considerable periods of PLMS. However, PLMS may occur in patients without RLS symptoms during wakefulness.
• RLS and PLMS are typically diagnosed by patient history and standardized questionnaires as well as by polysomnographic evaluation.
• a ten-question evaluation scale developed by the International RLS study group (IRLSSG) has been found to be useful for assessment of RLS severity for purposes of clinical assessment, research, or therapeutic trials.
• Standardized tests such as the Suggested Immobilization Test and the Forced Immobilization Test for quantification of RLS or PLM have been proposed.
• RLS/PLMS Reduction of iron content of the brain and other fluids/compartments of the body as well as reduced dopamine synthesis in the brain have been proposed in RLS.
• Dopamine is a neurotransmitter synthesized in the brain and with essential features for adequate central nervous system (CNS) function.
• CNS central nervous system
• Iron is a cofactor for the enzyme tyrosine hydroxylase which is the rate-limiting step in dopamine metabolism.
• experimental data points to iron as an essential component for adequate transmembraneous transport of dopamine and dopamine receptor function in CNS regions responsible for motor and sensory function. Iron deficiency, by its potential effects on dopamine system activity has been identified as an important component in RLS pathophysiology.
• RLS treatment modalities
• these include the administration of dopamine receptor agonists, other dopaminergic agents, benzodiazepines, opiates and anti-convulsants.
• dopamine receptor agonists include the administration of dopamine receptor agonists, other dopaminergic agents, benzodiazepines, opiates and anti-convulsants.
• the use of several of these agents is hampered by undesirable side effects that, depending on the substance, include nausea, vomiting, insomnia, daytime sedation, cognitive side effects, allergic reactions, anaphylactic shock etc.
• Certain forms of RLS so called secondary RLS a condition that is related to e.g. pregnancy or end-stage renal disease, may be specifically resolved be treatment or elimination of the underlying condition/disease. In these cases there may a profound reduction or even complete remission of RLS following treatment.
• a further object of the present invention is to provide a diagnostic tool for detection the presence of RLS/PLMW and PLMS in a patient and a corresponding diagnostic method.
• a method of treating RLS including PLMS and PLMW comprising the joint administration of an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent, and iron in a biologically usable form, in pharmacologically effective combined amounts.
• an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent and iron in a biologically usable form, in pharmacologically effective combined amounts.
• the administration of these combined amounts is more effective than the separate unrelated administration of a corresponding amount of the agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent and a corresponding amount of iron in a biologically usable form.
• iron in a biologically usable form advantageously enhances the RLS dampening effect of the agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent.
• a pharmacologically effective amount of the agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent or a combination of several of such agents an is one which eliminates or substantially reduces or dampens the manifestations of RLS over a period of time, such as during the afternoon, evening, and even during nocturnal or other sleep periods of from 10 minutes to 10 hours.
• the agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent is also referred to as “dopaminergic agent” or “DA agent”.
• iron in a biologically usable form is referred to as "IR”.
• Biologically usable form relates to a form in which the iron can be taken up by the gastrointestinal mucosa tract or which is used by the body for restoring depleted iron stores upon injection or infusion.
• DA agent/IR the combination of the agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent, and of iron in a biologically usable form.
• “Joint administration” indicates administration in a time-wise defined manner, either simultaneously or about simultaneously, or consecutive.
• “Joint administration” includes administration of the components of DA agent/IR in separate overlapping administration schemes.
• Dopamine has been used for decades to treat a number of conditions including RLS.
• Other recognized and documented indications for dopamine include Morbus Parkinson (cerebral D2 and D3 receptors), heart failure and cardiogenic shock (vascular Dl receptors).
• Morbus Parkinson Cerebral D2 and D3 receptors
• heart failure vascular Dl receptors
• cardiogenic shock vascular Dl receptors
• Dopamine and central nervous dopaminergic effect promoting agents particularly useful in the invention include carbidopa and levodopa, dopamine, dobutamine, dopamine agonists like ropinerol, cabergoline, pramipexole, pergolide, rotigotine, lisuride and bromocriptine, as well as dopamine promoting MAO-B inhibitors like e.g. selegiline, rasagiline and safinamide, and dopamine reuptake inhibitors like e.g.
• vanoxerine GRR 12909
• radafaxine and SEP 226 330
• pharmaceutically acceptable salts including pharmaceutically acceptable salts, enantiomers of those in the aforementioned compounds which are able to form salt with organic or inorganic acids.
• the aforementioned compounds are extensively described in the literature; see, for instance: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th Ed., Pergamon Press, New York, 2001 and Martindale The Complete Drug Reference 34th Ed., Pharmaceutical Press, New York, 2005 and the references cited therein.
• pharmaceutical compositions useful in the invention are described for a number of DA agents. All different chemical structures and specifically salts being only slightly soluble in aqueous solutions are included in the invention. This is specifically true for those chemical structures which may be of particular interest in the manufacture of controlled release DA agent/IR compositions.
• a potential DA agent /TR mixture is advantageously formulated in a way appropriate to the chosen administration route.
• the positive effect of IR in the treatment of RLS may be due to an enhancement of dopaminergic activity in the central nervous system thereby mimicking the effects of dopamine described above. While this hypothesis may provide a scientifically attractive explanation for the observed effect of said IR, it must be emphasized that this must not be considered to be binding in any way on the concept and the working of the present invention.
• the IR in a biologically usable form of the invention is preferably a salt of Fe 2+ , with an acid, more preferred with an organic acid or a hydroxide of Fe 2+ .
• Preferred organic acids comprise ascorbic, aspartic, fumaric, gluconic, and succinic acid.
• Preferred inorganic acids comprise hydrochloric acid and sulphuric acid.
• the IR of the invention may be stabilised by complex formation such as with dextran, sorbitol, and sucrose.
• IR particularly useful in the invention includes ferrous fumarate, ferrous sulphate, ferrous gluconate, sodium ferrous gluconate, carbohydrate complexes of Fe++, such as iron dextran, iron sorbitol, iron sucrose in form of capsules, extended- release capsules, solutions, lozenges, syrups, suspensions, tablets, including chewable tablets, for per-oral administration, and aqueous solutions for parenteral administration.
• Preferred for intra-muscular injection is iron sorbitol, iron sucrose, and iron dextran in an aqueous carrier.
• the DA agent/IR combination of the invention which may comprise a mixture of several DA combined with an IR or several IR combined with a DA or several DA combined with several IR, can be administered by various routes.
• the most preferred route is by per-oral administration, in which case the pharmaceutical preparation
• the agent of the invention may be designed for preferred uptake through the oral mucosa, such as by sub-lingual uptake.
• a preparation that releases the DA/IR agent of the invention so as to obtain essentially gastrointestinal absorption.
• the peroral or parenteral administration of the DA agent and the IR is by separate pharmaceutical preparations which may be administered simultaneously or within a short period of time, such as within one or five or ten minutes or consecutively in intervals of up to 30 min or 2 hrs and even 12 or 24 hrs and more.
• a pharmaceutical composition comprising an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent, and iron in a biologically usable form, in a combined amount pharmacologically effective in the treatment of RLS.
• a combination package comprising an IR preparation for intravenous infusion, in particular for a number of scheduled separate infusions to be administered during one or several weeks or even one month or more, and several dosages of a per-oral preparation comprising a DA agent for repeated administration over a period of time identical or overlapping the period of infusion of the IR preparation, such as on a daily or weekly basis.
• the dosages applied in such combination packages will be based on efficacy data routinely determined by clinical studies (e.g. repeated IR infusions of 1 g of iron sucrose in total for a three months period in combination with a once daily intake of 0.35 mg pramipexole.
• Another example of a combination package of the invention for per-oral administration of DA and IR comprises a tablet comprising 100 mg of ferrous sulphate in combination with a tablet comprising 0.35 mg of pramipexole.
• a DA agent with a short pharmacological half-life it is desirable to design an oral, buccal or sublingual pharmaceutical formulation for sustained release of the DA agent/IR combination of the invention to avoid the need af frequent administration which would be particularly difficult during sleep.
• a suitable solution for this problem would be a fixation, at least for a certain period of time, of one or both components of the formulation containing the DA agent/IR combination in or near the sublingual region. This could be done by a device for fixation or a holding the tablet, lozenge, or similar attached to one or several teeth of the lower jaw, or by implantation of a holding means, of titanium, for instance, in the lower jaw.
• Such holding means could also be used for holding a small plastic container enclosing a liquid or solid pharmaceutical composition of the DA of the invention, from which container the solution would leak through a minute opening or through a system of micropores driven by, for example, osmotic pressure. It is also possible to incorporate the compound of the invention in polymer matrix, biodegradable or not, from which it could leak slowly into the oral cavity.
• Appropriate technology for producing biodegradable polyester matrices of the polylactide/polyglycolide type for incorporation and sustained release of pharmacologically active compounds is described in, for instance, L A Sanders et al., J Pharmaceutical Sci. 75 (1986) 356-360, and in the U.S. Patent No. 3,773,919 (Boswell).
• Non-degradable polymers of appropriate physical properties can also be used as matrices.
• the amount of DA agent and IR to be administered in combination for treatment of RLS will vary depending on factors such as the particular chemical nature of the DA agent/IR formulation used, the route of administration, the release profile of the formulation into which it is incorporated, the severity of the disease, individual pharmacokinetic and pharmacodynamic properties as well as the status of the patient.
• the dose range for per-oral administration of pramipexole will be from 0.009 to 1 mg per 24 hours. Normally, an amount of from 0.18 to 0.5 mg of pramipexole is envisaged as the normal range used for a per oral administration to an adult person.
• the dosage range for an IR preparation like iron sucrose may vary between 200 and 2000 mg.
• the appropriate dose range for a particular DA agent or IR or the combination of a DA agent and an IR can be determined by titration in routine experiments.
• the DA agent can be efficiently administered also by inhalation, such as inhalation via the mouth or via the nose.
• the nasal mucosa is easily accessible by use of extra- or intranasal devices, the later ones appropriately shaped and designed similarly to what has been described above for intraoral and sublingual administration.
• the transdermal formulation comprising the DA agent of the invention is specifically advantageous in regard of simplicity and from a patient comfort standpoint.
• the agent is applied to the skin in form of a viscous ointment or similar.
• Transdermal systems (patches provided with a liquid or semi-liquid pharmaceutical composition) for controlled drug delivery through the skin are well known in the art, for instance formulations used for administration of nicotine and drugs used for diseases of the circulatory system.
• composition and/or device comprising the DA agent/IR combination of the invention will depend on the particular compound, its rate of absorption through the mucosa or the skin, the release profile of the respective sustained release formulation and/or device, if used, and similar.
• administration of the DA agent/IR combination will, in the majority of cases, have to start well in advance of the RLS symptoms period to achieve optimal effect, for instance from 10 minutes to 6 hours prior to the onset of sleep.
• the DA agent/IR combination of the invention may also be combined, in one and the same pharmaceutical preparation, with other pharmacologically active compounds useful in the treatment of RLS/PLMS.
• the DA agent/IR combination of the invention may also be used for diagnosing RLS and thereby to dissociate this condition from other types of sleep disorders.
• the diagnostic method according to the invention comprises administration to the patient a DA agent/IR combination given in increasing amounts prior to or during a series of day/evening/sleep periods; administration can be in single or multiple doses.
• the observation of a reduction of the severity and/or RLS events or episodes or reduced daytime sleepiness/increased alertness is indicative of the presence of RLS.
• Fig. 1 is a diagram illustrating the clinical evaluation of two patients with RLS upon administration of iron sucrose and pramipexole;
• Fig. 2 is a diagram illustrating the clinical evaluation of a third patient with RLS upon administration of a fixed combination of L-dopa and carbidopa, and iron dextran.
• EXAMPLE 1 Single-blind, uncontrolled treatment studies with DA and iron sucrose in three different patients with restless legs
• IRLSS Score 30 and 28 respectively were studied. Pramipexole (in form of the dihydrochloride monohydrate) 0.35 mg given once daily by an evening dose for 21 days, resulted in a mean reduction of PLMI from 3 to 0, and from 17 to 2, and the IRLSS score was reduced from 30 at baseline to 15 at day 21 and from 28 to 17, respectively (Fig. 1; B). No side effects were reported during the study from neither of the patients. Due to remaining RLS complaints iron sucrose therapy in the dosage 500 mg i.v. twice, was introduced during one week (Fig. 1 ; C). Both patients were free of any RLS complaints when assessments were performed 3 weeks after the last infusion of iron sucrose.
• Serum ferritin levels increased from 30/45 mg/dl at baseline to 130/145 mg/dl after iron sucrose infusions. Patients discontinued pramipexole treatment for one week and symptoms reoccurred (IRLSS scale after one treatment pause of pramipexole 14 and 18. Fig. 1; D). However, the baseline values of 30 and 28 in the IRLSS scale were not reached. Following reintroduction of pramipexole in the previously used dosages, the IRLSS score after 12 weeks was found to be 0 and 4 in the two patients (Fig. 1 ; E).
• EXAMPLE 2 A subsequent clinical observational study included a patient with clinical symptoms of RLS and an IRLSS score of 26 on the diagnostic evaluation under treatment with L-dopa (levodopa) and carbidopa (Sinemet®, fixed combination dosage of 100 mg L-dopa and 25 mg carbidopa) (Fig. 2; A). The patient needed to be treated with altogether three tablets per evening in order to obtain acceptable symptom relief (IRLSS score 4. Fig. 2; B). However, this patient complained of considerable gastrointestinal side effects including nausea and vomiting when the treatment was optimized. In addition, following two months of treatment this patient had started to suffer from significant symptoms suggestive of augmentation evidenced by an onset of RLS symptoms in the early afternoon.

Landscapes

• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Emergency Medicine (AREA)
• Inorganic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=38188943

Family Applications (1)

Country Status (11)

Cited By (1)

Families Citing this family (1)

Citations (4)

Family Cites Families (1)

• 2006
  • 2006-12-06 EA EA200801540A patent/EA200801540A1/ru unknown
  • 2006-12-06 EP EP06824619A patent/EP1973551A1/en not_active Withdrawn
  • 2006-12-06 AU AU2006327254A patent/AU2006327254A1/en not_active Abandoned
  • 2006-12-06 US US12/158,172 patent/US20090304816A1/en not_active Abandoned
  • 2006-12-06 WO PCT/SE2006/050553 patent/WO2007073325A1/en not_active Ceased
  • 2006-12-06 KR KR1020087017787A patent/KR20080078075A/ko not_active Withdrawn
  • 2006-12-06 JP JP2008547181A patent/JP2009520023A/ja active Pending
  • 2006-12-06 CN CNA2006800517948A patent/CN101336109A/zh active Pending
  • 2006-12-06 CA CA002634140A patent/CA2634140A1/en not_active Abandoned
• 2008
  • 2008-06-19 IL IL192325A patent/IL192325A0/en unknown
  • 2008-06-19 ZA ZA200805358A patent/ZA200805358B/xx unknown

Patent Citations (4)

Non-Patent Citations (12)

Also Published As

Similar Documents

Legal Events